Critique of Proton Therapy Survival Claims in Oropharyngeal Cancer

This correspondence published in The Lancet critically analyzes the results of a phase 3 clinical trial conducted by Steven J. Frank and colleagues regarding proton therapy for oropharyngeal cancer. The authors argue that the reported improvement in overall survival, despite equivalent progression-free survival compared to photon therapy, likely stems from confounding factors rather than genuine therapeutic efficacy. A central point of contention is the discrepancy between intention-to-treat and per-protocol analyses. The critics note that if proton therapy truly enhanced survival, the observed difference should have been attenuated when accounting for patients who crossed over from photon to proton therapy, assuming no extreme bias in the crossover population. However, this attenuation was not demonstrated in the trial data. Consequently, the correspondence suggests that the claimed survival benefits may be misleading. This analysis highlights the complexities involved in interpreting local therapy trials where survival metrics diverge, urging caution in accepting the superiority of proton therapy based on the current evidence. The piece serves as a scientific rebuttal aimed at clarifying statistical interpretations in oncology research.